Analysis and warning of adverse reactions of 42 cases of severe myelosuppression caused by antineoplastic drugs
Objective To analyze the characteristics and regularities of adverse drug reactions(ADR)of severe myelosuppression caused by antineoplastic drugs in our hospital,provide reference and warning for clinical.Methods Totally 42 reports about ADR of severe myelosuppression caused by antineoplastic drugs reported to the national adverse drug reaction monitoring center between January 1,2020 to December 31,2022 were collected and retrospectively analyzed based on the tumor type,tumor stage,treatment plan,personal risk factors,myelosuppression type,occurrence time and preventive measures.Results Amon the 42 reports of ADR,24 females involved(57.14%)and 18 males involved(42.84%).Most of the tumor patients with staged IV(78.57%),the percentage of middle-aged(45～59 years old)and elderly(60～74 years old)was the highest(73.81%).Intravenous administration is the most common route of administration(90.48%).66.67%of ADRs occurred at 4～9 d after treatment.The combination of two cytotoxic drugs is the most common anti-tumor therapy(47.62%),the largest proportion involved were platinum drugs(31.58%)and plant-derived drugs(26.32%).14 patients(33.33%)had the indication of prophylactic administration of human granulocyte colony stimulating factor(G-CSF),but none of them were used.35 patients(83.33%)were cured or improved after treatment,3 patients did not improve,and 4 patients died.Conclusion Monitoring of special populations and high-risk drugs,pharmaceutical care should be strengthened.Take corresponding preventive measures when necessary,to prevent or reduce the occurrence of severe myelosuppression ADRs.
Antineoplastic drugsAdverse drug reactionsSevere myelosuppressionPharmacovigilance
NETL
NSTL
万方数据
维普
